Subcontracting Opportunities
Subcontracting allows small and disadvantaged businesses to substantially impact the federal procurement preference programs. Due to legislative mandates, federal prime contractors award billions of subcontracting dollars annually to small businesses—Small Business Subcontracting Plan requirements set forth in their contracts include requirements to track participation by veteran-owned, service-disabled veteran-owned, HUBZone, disadvantaged, and women-owned businesses.
USASpending.gov provides information on organizations who have a prime contractor relationship with the NCI. The current Frederick National Laboratory for Cancer Research (FNLCR) prime contractor has significant subcontracting opportunities—see FNLCR Acquisitions for further information.
NCI also maintains a list of its active Indefinite Delivery/Indefinite Quantity (ID/IQ) Prime Contractors. NCI encourages businesses to network and establish teaming arrangements to support these contracting vehicles, which are used to place a variety of orders for supplies and services through processes that do not involve public posting after the base ID/IQ contract(s) have been awarded.
| Contract Name(s) | Contract Specialist | Title & Brief Description From Article B.1. | Base Period of Performance (Start-End Dates) |
|---|---|---|---|
| PR Strategist | Megan Kisamore | NCI/OWPD workforce training and facilitation Services | 2/19/2020 - 2/18/2025 |
| PBG Consulting LLC | Monico Luna | NCI CSSI Technical, Programmatic and Other Support Services | 7/15/2020 - 7/14/2025 |
| Booz Allen Hamilton | Antoinette Robinson | Biomedical Information Management and Analytic Support Services | 9/16/2020 - 9/15/2025 |
| Deloitte | Antoinette Robinson | Biomedical Information Management and Analytic Support Services | 9/16/2020 - 9/15/2025 |
| Information Management Services, Inc. | Antoinette Robinson | Biomedical Information Management and Analytic Support Services | 9/16/2020 - 9/15/2025 |
| Research Triangle Institute | Antoinette Robinson | Biomedical Information Management and Analytic Support Services | 9/16/2020 - 9/15/2025 |
| Westat | Antoinette Robinson | Biomedical Information Management and Analytic Support Services | 9/16/2020 - 9/15/2025 |
| Cornerstone Systems Northwest | Angela Moore | Technical and logistical support to facilitate collaborative efforts of the CISNET Consortium in cancer surveillance | 4/28/2021 - 4/27/2026 |
| North American Association of Central Cancer Registries (NAACCR) | Kate Muir | Support Services for Developing and Promoting Methods and Standards for Cancer Registry Operations and Surveillance Data | 7/1/2021 - 6/30/2026 |
| IMS | Sheila Ramos | Biomedical Computing, Analytic and Data Management | 7/31/2021 - 7/30/2026 |
| ICF | Sheila Ramos | Biomedical Computing, Analytic and Data Management | 8/1/2021 - 7/31/2026 |
| Westat | Sheila Ramos | Biomedical Computing, Analytic and Data Management | 8/1/2021 - 7/31/2026 |
| Van Andel Research Institute | Mataya Robinson | Cancer Moonshot Biobank Biospecimen Core | 6/28/2022 - 6/27/2027 |
| American Type Culture Collection | Kristi-Jo Noel | DCEG Field and Biospecimen Support Services - provide technical support for studies and other research activities associated with ongoing and new research programs | 7/1/2022 - 6/30/2027 |
| Coriell | Kristi-Jo Noel | DCEG Field and Biospecimen Support Services - provide technical support for studies and other research activities associated with ongoing and new research programs | 7/1/2022 - 6/30/2027 |
| ICF | Kristi-Jo Noel | DCEG Field and Biospecimen Support Services - provide technical support for studies and other research activities associated with ongoing and new research programs | 7/1/2022 - 6/30/2027 |
| Social & Scientific Systems | Kristi-Jo Noel | DCEG Field and Biospecimen Support Services - provide technical support for studies and other research activities associated with ongoing and new research programs | 7/1/2022 - 6/30/2027 |
| Westat | Kristi-Jo Noel | DCEG Field and Biospecimen Support Services - provide technical support for studies and other research activities associated with ongoing and new research programs | 7/1/2022 - 6/30/2027 |
| Westat | Chris Shih | Cancer Trials Support Unit: TA 2-CTSU Core Support, TA 4-Site Study Setup and TA 6-electronic Patient Reported Outcomes development and support. | 8/1/2022 - 7/31/2027 |
| PPD Development LLP | Whitney Monkam | Cancer Trials Support Unit: TA 2-CTSU Core Support, TA 4-Site Study Setup and TA 6-electronic Patient Reported Outcomes development and support. | 8/1/2022 - 7/31/2027 |
| EDJ Associates | Julia Tilton | Cancer Trials Support Unit: TA 2-CTSU Core Support, TA 4-Site Study Setup and TA 6-electronic Patient Reported Outcomes development and support. | 8/1/2022 - 7/31/2027 |
| Technical Resources International, Inc. | Julia Tilton | Cancer Trials Support Unit: TA 2-CTSU Core Support, TA 4-Site Study Setup and TA 6-electronic Patient Reported Outcomes development and support. | 8/1/2022 - 7/31/2027 |
| Essex Management | Whitney Monkam | Cancer Trials Support Unit: TA 2-CTSU Core Support, TA 4-Site Study Setup and TA 6-electronic Patient Reported Outcomes development and support. | 8/1/2022 - 7/31/2027 |
| Strategix Management LLC | Eve Van Buren | Tobacco Control Research Branch Scientific and Logistical Services Support | 8/1/2022 - 7/31/2027 |
| Fisher BioServices, Inc. | Mesfin Alemayehu | Registration, Storage and Distribution of Chemicals and Drugs for Pre-Clinical Discovery, Evaluation and Development | 3/1/2023 - 2/29/2028 |
| Alchem Laboratories Corp | Paula Wilkison | Analysis and Synthesis of GMP and non-GMP Bulk Drugs and Pharmaceutical Formulations | 4/11/2023 - 4/10/2028 |
| MRIGlobal | Paula Wilkison | Analysis and Synthesis of GMP and non-GMP Bulk Drugs and Pharmaceutical Formulations | 4/11/2023 - 4/10/2028 |
| Research Triangle Institute (RTI) | Mataya Robinson | Analysis and Synthesis of GMP and non-GMP Bulk Drugs and Pharmaceutical Formulations | 4/11/2023 - 4/10/2028 |
| SRI International | Mataya Robinson | Analysis and Synthesis of GMP and non-GMP Bulk Drugs and Pharmaceutical Formulations | 4/11/2023 - 4/10/2028 |
| Arkansas Department of Health | Jim French | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2021 - 4/30/2028 |
| California Department of Public Health | Kate Muir | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 7/15/2021 - 4/30/2028 |
| Colorado Department of Public Health and Enviornment | Jim French | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2021 - 4/30/2028 |
| Connecticut Department of Public Health | Angela Moore | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| Emory University | Kate Muir | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| Fred Hutchinson Cancer Center | Angela Moore | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| Health Research, Inc. | Angela Moore | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| Idaho Hospital Association | Michelle Nguyen | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| Illinois Department of Public Health | Michelle Nguyen | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 3/3/2021 - 4/30/2028 |
| Louisiana State University | Angela Moore | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| Massachusetts Department of Public Health | Angela Moore | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| Michigan Department of Health and Human Services | Angela Moore | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| Oregon Health & Science University | Michelle Nguyen | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| Public Health Institute | Kate Muir | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| Rutgers State University | Michelle Nguyen | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 3/3/2021 - 4/30/2028 |
| Tennessee Department of Health | Jim French | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| Texas Department of State Health Services | Jim French | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 3/3/2021 - 4/30/2028 |
| The Curators of the University of Missouri | Angela Moore | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 3/3/2021 - 4/30/2028 |
| Trustees of Dartmouth College | Michelle Nguyen | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2021 - 4/30/2028 |
| UCSF | Kate Muir | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2021 - 4/30/2028 |
| University of Hawaii | Kate Muir | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2021 - 4/30/2028 |
| University of Iowa | Jim French | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2021 - 4/30/2028 |
| University of Kentucky (Research Foundation) | Michelle Nguyen | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2021 - 4/30/2028 |
| University of New Mexico | Jim French | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2021 - 4/30/2028 |
| University of Southern California | Kate Muir | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2021 - 4/30/2028 |
| University of Utah | Jim French | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2021 - 4/30/2028 |
| Wayne State University | Michelle Nguyen | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2021 - 4/30/2028 |
| Wisconsin Department of Health Services | Michelle Nguyen | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2021 - 4/30/2028 |
| Henry Ford Health System | Bryan Dankanich | The Contractor shall recruit and retain participants, collect and process biospecimens, administer online questionnaires, and link to electronic medical records in support DCEG's NextGeneration Cohort | 6/4/2018 - 6/3/2028 |
| Kaiser Foundation Hospitals | Tyler Kosh | The Contractor shall recruit and retain participants, collect and process biospecimens, administer online questionnaires, and link to electronic medical records in support DCEG's NextGeneration Cohort | 6/4/2018 - 6/3/2028 |
| Sanford Research | Bryan Dankanich | The Contractor shall recruit and retain participants, collect and process biospecimens, administer online questionnaires, and link to electronic medical records in support DCEG's NextGeneration Cohort | 6/4/2018 - 6/3/2028 |
| The University of Chicago | Tyler Kosh | The Contractor shall recruit and retain participants, collect and process biospecimens, administer online questionnaires, and link to electronic medical records in support DCEG's NextGeneration Cohort | 6/4/2018 - 6/3/2028 |
| MRIGlobal | Paula Wilkison | Centralized Chemopreventive Agent Repository and Chemistry Support Services | 7/1/2023 - 6/30/2028 |
| Medidata Solutions | Chris Shih | Rave Hosting, Maintenance, and Professional Services, and License, Hosting, Maintenance, and Professional Services for Rave integrated anicillary services. | 9/1/2023 - 8/31/2028 |
| University of Pittsburgh | Antoinette Robinson | The objective of the "Preclinical Pharmacokinetic and Pharmacology Evaluations of Agents Being Developed for Cancer Patients" acquisition is to acquire research & development services (through a multiple-award Indefinite Delivery/Indefinite Quantity (IDIQ) pool) to support the NCI Experimental Therapeutics (NExT) Program in the discovery and development of agents with clinical anticancer activity. Specifically, the Contractor shall provide services for implementation of bioanalytical methods and conduct of pharmacokinetic evaluations in animals with compounds of interest to the NExT program. Analysis of samples provided by the NCI from other sources, including human materials, may also be requested. | 9/27/2021 - 9/26/2028 |
| Mayo Clinic | Antoinette Robinson | The objective of the "Preclinical Pharmacokinetic and Pharmacology Evaluations of Agents Being Developed for Cancer Patients" acquisition is to acquire research & development services (through a multiple-award Indefinite Delivery/Indefinite Quantity (IDIQ) pool) to support the NCI Experimental Therapeutics (NExT) Program in the discovery and development of agents with clinical anticancer activity. Specifically, the Contractor shall provide services for implementation of bioanalytical methods and conduct of pharmacokinetic evaluations in animals with compounds of interest to the NExT program. Analysis of samples provided by the NCI from other sources, including human materials, may also be requested. | 9/27/2021 - 9/26/2028 |
| SRI International | Antoinette Robinson | The objective of the "Preclinical Pharmacokinetic and Pharmacology Evaluations of Agents Being Developed for Cancer Patients" acquisition is to acquire research & development services (through a multiple-award Indefinite Delivery/Indefinite Quantity (IDIQ) pool) to support the NCI Experimental Therapeutics (NExT) Program in the discovery and development of agents with clinical anticancer activity. Specifically, the Contractor shall provide services for implementation of bioanalytical methods and conduct of pharmacokinetic evaluations in animals with compounds of interest to the NExT program. Analysis of samples provided by the NCI from other sources, including human materials, may also be requested. | 9/27/2021 - 9/26/2028 |
| IIT Research Institute | Rachel Turk | PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers | 1/25/2024 - 1/24/2029 |
| University of Illinois at Chicago | Rachel Turk | PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers | 1/25/2024 - 1/24/2029 |
| Institute For Cancer Research, Fox Chase Cancer Center | Erin Dwyer | PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers | 1/25/2024 - 1/24/2029 |
| University of Texas MD Anderson Cancer Center | Erin Dwyer | PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers | 1/25/2024 - 1/24/2029 |
| University of Oklahoma, | Kelly Fowler | PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers | 1/25/2024 - 1/24/2029 |
| Weill Medical College Of Cornell University | Rachel Turk | PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers | 1/25/2024 - 1/24/2029 |
| Curia Bio Inc | Megan Osele | PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers | 9/16/2024 - 1/24/2029 |
| Arbor Research, LLC | Randall Tiqui | NCI Center for Global Health, Coordination, Data Analysis, and Technical Support (CDATS) | 9/13/2024 - 9/12/2029 |
| IIT Research Institute | Whitney Monkam | Preclinical Toxicology of Small Molecule Drugs Developed for Cancer and Other Indications | 9/26/2022 - 9/25/2029 |
| GU RNPTS RMIECH | Kristi-Jo Noel | Cancer and Other Effects Following the Chernobyl Accident in Belarus | 2/15/2024 - 2/14/2034 |
| STCU | Kristi-Jo Noel | Cancer and Other Effects Following the Chernobyl Accident in Ukraine | 4/1/2024 - 3/31/2034 |
| Fundacion INCIENSA | Michele Brown | Epidemiology and Prevention of Infections and Related Diseases - (Evaluation HPV vaccines in Costa Rica) | 9/1/2024 - 8/31/2034 |
| Regimed Medical | Dana Summons | IDIQ for Supplies - Nilotinib Capsules | 3/27/2023 - 3/26/2027 |
| Kearney & Company, P.C. | Tim Corrigan | BPA for Auditing Services | 9/1/2021 - 8/31/2025 |
| AFG Construction Management | Tim Corrigan | BPA for Construction Quality Management Services | 8/15/2023 - 8/14/2028 |